The rise of Sildenafil initially sparked a period of growth for the drug industry, but recent shifts present a complicated scenario for shareholders. Off-patent versions are reducing revenue, and continued patent https://tamzinzwcf402457.vidublog.com/39882375/sildenafil-and-pharma-a-precarious-bet